WuXi Biologics (Cayman) Inc. (HKG:2269)

WuXi Biologics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,439	8,279	9,670	6,395	9,003	7,096
Short-Term Investments	3,158	1,907	340	304.47	1,148	1,272
Trading Asset Securities	942.76	523.59	1,234	2,015	975.58	112.47
Cash & Short-Term Investments	12,540	10,710	11,243	8,714	11,126	8,481
Cash Growth	31.60%	-4.75%	29.02%	-21.68%	31.20%	25.67%
Accounts Receivable	7,028	5,735	6,184	5,158	3,273	2,371
Other Receivables	793.04	639.86	490.64	616.59	908.05	349.37
Receivables	7,821	6,374	6,675	5,775	4,181	2,770
Inventory	1,655	1,522	1,766	2,281	1,687	1,084
Other Current Assets	2,431	4,967	1,514	1,700	2,535	1,870
Total Current Assets	24,447	23,573	21,198	18,470	19,530	14,204
Property, Plant & Equipment	30,175	28,435	29,939	25,916	19,756	12,870
Long-Term Investments	3,007	2,400	2,934	2,709	2,203	1,074
Goodwill	1,530	1,530	1,530	1,530	1,530	185.41
Other Intangible Assets	441.1	442.37	511.83	548.78	600.65	391.86
Long-Term Accounts Receivable	78.47	85.67	165.5	109.17	124.49	87.67
Long-Term Deferred Tax Assets	483.1	444.32	235.78	222.57	220.79	80.14
Other Long-Term Assets	276.26	66.78	60.69	58.88	68.42	70.35
Total Assets	60,437	56,977	56,576	49,564	44,033	28,964
Accounts Payable	969.43	747.15	833.27	794.39	617.78	646
Accrued Expenses	815.17	828.19	805.04	997.89	852.59	532.15
Current Portion of Long-Term Debt	2,548	2,435	576.33	1,321	2,122	767.13
Current Portion of Leases	436.06	183.7	154.98	149.06	103.56	60.71
Current Income Taxes Payable	518.46	647.66	618.88	773.83	557.73	250.89
Current Unearned Revenue	2,795	2,356	3,090	3,379	1,734	664.86
Other Current Liabilities	405.61	1,423	1,558	1,903	2,268	1,577
Total Current Liabilities	8,487	8,621	7,636	9,319	8,256	4,498
Long-Term Debt	185.14	200.9	1,571	1,462	640.51	1,838
Long-Term Leases	1,938	2,120	2,259	1,490	1,429	666.51
Long-Term Unearned Revenue	516.53	460.47	969.23	949.46	876.73	873.69
Long-Term Deferred Tax Liabilities	73.18	97.31	122.54	132.08	124.21	180.89
Other Long-Term Liabilities	171.81	-	-	-	-	7.26
Total Liabilities	11,372	11,500	12,558	13,351	11,326	8,064
Common Stock	0.22	0.23	0.24	0.23	0.24	0.23
Additional Paid-In Capital	-	23,532	24,489	22,102	27,044	15,950
Retained Earnings	-	18,334	14,978	11,578	7,158	3,769
Treasury Stock	-	-	-916.92	-	-2,517	-
Comprehensive Income & Other	44,952	-46.54	1,782	1,367	593.13	845.19
Total Common Equity	44,952	41,819	40,332	35,047	32,279	20,564
Minority Interest	4,113	3,658	3,686	1,166	427.57	334.95
Shareholders' Equity	49,065	45,478	44,018	36,213	32,706	20,899
Total Liabilities & Equity	60,437	56,977	56,576	49,564	44,033	28,964
Total Debt	5,107	4,940	4,561	4,422	4,295	3,332
Net Cash (Debt)	7,433	5,770	6,682	4,293	6,831	5,149
Net Cash Growth	49.80%	-13.65%	55.66%	-37.16%	32.68%	13.04%
Net Cash Per Share	1.77	1.36	1.54	0.98	1.54	1.22
Filing Date Shares Outstanding	4,069	4,106	4,223	4,225	4,224	4,085
Total Common Shares Outstanding	4,069	4,106	4,223	4,225	4,224	4,085
Working Capital	15,959	14,952	13,562	9,151	11,274	9,706
Book Value Per Share	11.05	10.19	9.55	8.29	7.64	5.03
Tangible Book Value	42,981	39,847	38,290	32,969	30,148	19,987
Tangible Book Value Per Share	10.56	9.70	9.07	7.80	7.14	4.89
Land	-	7,701	6,195	2,114	2,097	301.16
Machinery	-	9,388	7,632	6,029	4,997	2,662
Construction In Progress	-	9,755	13,750	15,935	10,873	8,911
Leasehold Improvements	-	3,764	3,357	2,581	1,795	1,305
Order Backlog	-	135,033	-	-	86,376	73,930

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.